Docetaxel is under clinical development by Plus Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
docetaxel (ATI-1123) is under development for the treatment of solid tumors such as breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, thyroid cancer, gastric cancer, uterine cancer, urachal cancer, cervical cancer, prostate cancer, soft-tissue sarcoma and melanoma. ATI-1123 is with a brand name DocePlus is administered through intravenous route and by drip. It acts by targeting beta tubulin. It is developed based on protein stabilized liposome (PSL) nanotechnology.
It was also under development for the treatment of small cell lung cancer.
Plus Therapeutics overview
Plus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.